Have you read these stories?

In war with HUL, Ruchi Soya is Ramdev's secret weapon

Patanjali will touch Rs 25,000 crore in revenue by the end of the current fiscal year.
The Economic Times



Ranitidine recall impacts Dr Reddy's P&L by Rs 40-crore

Dr Reddy's Laboratories which initiated a voluntary recall of its Ranitidine at the retail level for over-the-counter products and at the consumer level sold in the US due to confirmed contamination with N-Nitrosodimethylamine established by FDA following the ongoing investigation which reported carcinogenic impurity in the drug at low levels.

Share market update: Nifty Pharma index up; Dr. Reddy's Lab rises 1%

The Nifty Pharma index was trading 0.14 per cent up at 8118.65 around 10...

HSBC maintains hold on Dr Reddy's, revises target price to Rs 2,760

Hold Dr. Reddy's Laboratories Ltd. at a price target of Rs 2760.0 .

ET Prime Distribution
Load More...

Other useful Links

Copyright © 2020 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service